Prognostic relevance of metabolic approach in patients with heart failure

Current Pharmaceutical Design

Volumn 15, Issue 8, 2009, Pages 883-892

  Di Napoli, Pericle ^a   Barsotti, Antonio ^b  

^a Heart Failure Unit   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Coronary artery disease; Heart metabolism; Left ventricle function; Prognosis; Trimetazidine

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ADENOSINE TRIPHOSPHATE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARNITINE PALMITOYLTRANSFERASE I; CREATINE PHOSPHATE; DEATH RECEPTOR; DEATH RECEPTOR 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; FAS LIGAND; OXYGEN RADICAL; PLACEBO; TRIMETAZIDINE; TROPONIN T; TUMOR NECROSIS FACTOR RECEPTOR;

ACIDOSIS; ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CALCIUM CELL LEVEL; CARDIOMYOPATHY; CELL DAMAGE; CELL DEATH; CELL METABOLISM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENERGY METABOLISM; FATTY ACID OXIDATION; GLUCOSE OXIDATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; KIDNEY FUNCTION; LIPID OXIDATION; LOW DRUG DOSE; MITOCHONDRION; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SODIUM CELL LEVEL; TREATMENT DURATION;

HEART FAILURE; HUMANS; PROGNOSIS; RISK ASSESSMENT; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 65649137713     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582147     Document Type: Review

References (84)

1. Dyer M, Cowie MR. Heart Failure: Diagnosis and healthcare burden. Clin Med 2004; 4: 13-8.
2. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29(19): 2388-442.
3. Hogg K, Swedberg K, McMuray J. Heart failure with preserved left ventricular function. epidemiology, clinical characteristics and prognosis. J Am Coll Cardiol 2004; 43: 317-27.
4. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention Trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-7.
5. Carson P, Anand I, O'Connor C Jaski B, Steinberg J, Lwin A, et al. Mode of death in advanced heart failure: The Comparison of Medical, Pacing, and Defibrillator Therapies in Heart Failure (COMPANION) Trial. J Am Coll Cardiol 2005; 46: 2329-34.
6. Frenneaux MP. Autonomic changes in patients with heart failure and in post-myocardial infarction patients. Heart 2004; 90: 1248-55
7. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-18
8. Neubauer S. The failing heart: An engine out of fuel. N Engl J Med 2007; 356: 1140-51.
9. Jaswal JS, Cadete V, Lopaschuk G. Optimizing cardiac energy substrate metabolism: A novel therapeutic intervention for ischemic heart disease. Heart Metab 2008; 38: 5-14.
10. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat Cardiovasc Med 2006; 9: 490-8.
11. Stanley WC, Recchi FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005: 1093-129.
12. Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994; 43: 174-9.
13. Taylor M, Wallhaus TR, DeGrado TR, Russell DC, Stanko P, Nickles RJ, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid [F]FDG in patients with congestive heart failure. J Nucl Med 2001; 42: 55-62.
14. 123I BMIPP SPECT: Correlation with clinicopathological findings and clinical course. Heart 1999; 81: 153-9.
15. Dávila-Román VG, Vedala G, Herrero P, de las FL, Rogers JG, Kelly DP, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 271-7.
16. Essop MF, Opie LH. Metabolic therapy for the heart. Eur Heart J 2004; 25: 1765-8.
17. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug Trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl Coenzyme A thiolase. Circ Res 2000; 86: 580-8.
18. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994; 94: 1621-8.
19. Gottlieb RA, Engler RL. Apoptosis in myocardial ischemia-reperfusion. Ann NY Acad Sci 1999; 874: 412-26.
20. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996; 79: 949-56.
21. Elsasser A, Suzuki K, Lorenz-Meyer S, Bode C, Schaper J. The role of apoptosis in myocardial ischemia: A critical appraisal. Basic Res Cardiol 2001; 96: 219-26.
22. Haunstetter A, Izumo S. Apoptosis: Basic mechanisms and implications for cardiovascular disease. Circ Res 1998; 82: 1111-29.
23. Feuerstein, GZ, Young PR. Apoptosis in cardiac diseases: Stress-and mitogen-activated signaling pathways. Cardiovasc Res 2000; 45: 560-9
24. Valen G. The basic biology of apoptosis and its implications for cardiac function and viability. Ann Thorac Surg 2003; 75: S656-60.
25. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin induced heart failure: Mechanism and modulation. Mol Cell Biochem 2000; 207: 77-86.
26. Majno G, Joris I. Apoptosis, oncosis and necrosis: An overview of cell death. Am J Pathol 1995; 146: 3-15.
27. Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 2000; 45: 528-37.
28. Wang, J; Lenardo MJ. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 2000; 113: 753-7.
29. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116: 205-19.
30. Zoratti M, Szab I. The mitochondrial permeability transition. Biochim Biophys Acta 1995; 1241: 139-76.
31. Bishopric NH, Andreka P, Slepak TI. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opin Pharmacol 2001; 1: 141-50.
32. Cory S, Huang DC, Adams JM. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590-607.
33. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 3: 1899-911.
34. Mattson MP, Kroemer G. Mitochondria in cell death: Novel targets for neuroprotection and cardioprotection. Trends Mol Med 2003; 9: 196-205
35. Scarabelli TM, Knight R, Stephanou A. Clinical implications of apoptosis in ischemic myocardium. Curr Probl Cardiol 2006; 31: 181-264.
36. Di Napoli P, Taccardi AA, Grilli A, Felaco M, De Caterina R, Barsotti A. Left ventricular wall stress as a direct correlate of cardiomyocyte apoptosis in patients with severe dilated cardiomyopathy. Am Heart J 2003; 146: 1105-11.
37. Barsotti A, Di Napoli P. Trimetazidine and cardioprotection during ischemia-reperfusion. Ital Heart J 2004; 5: 29S-36.
38. Lopaschuk GD, Saddik M. The relative contribution of glucose and fatty acids to ATP production in hearts reperfused following ischemia. Mol Cell Biochem 1992; 116: 111-6.
39. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet 1994; 343: 155-8.
40. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalán R, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation 1998; 98: 2227-34.
41. El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A, et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res 2000; 47: 688-96
42. Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: A pharmacological preconditioning? Pharmacol Res 2002; 45: 69-72.
43. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27: 942-428.
44. Di Pasquale P, Lo Verso P, Bucca V, Cannizzaro S, Scalzo S, Maringhini G, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: Shortterm and long-term results. Cardiovasc Drugs Ther 1999; 13: 423-8.
45. Ruixing Y, Wenwu L, Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia reperfusion. Transl Res 2007; 149: 152-60.
46. Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005; 39: 893-9.
47. Maridonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage reduced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985; 20: 148-51.
48. Guarnieri C, Muscari C. Anti oxy-radical properties of trimetazidine. Res Commun Chem Pathol Pharmacol 1989; 64: 215-25.
49. Williams FM, Tanda K, Kus M, Willians TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828-33.
50. Tritto I, Wang P, Kuppusamy P, Giraldez R, Zweier JL, Ambrosio G. et al. The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J Cardiovasc Pharmacol 2005; 46: 89-98.
51. Kuralay F, Altekin E, Yazlar AS, Onvural B, Goldeli O. Suppression of angioplasty-related inflammation by preprocedural treatment with trimetazidine. Tohoku J Exp Med 2006; 208: 203-12.
52. Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007; 7(2): 143-50.
53. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161-5.
54. Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: A post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol 2007; 50(5): 585-9.
55. Fragasso G, Piatti PM, Monti L, Palloshi A, Setola E, Puccetti P, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003; 146: E18-25.
56. Di Napoli P, Chierchia S, Taccardi AA, Grilli A, Felaco M, De Caterina R, et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide 2007; 16(2): 228-36.
57. Belardinelli R, Solenghi M, Volpe L, Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: An antioxidant effect. Eur Heart J 2007; 28: 1102-8.
58. Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW. Predicting mortality in patients with heart failure: A pragmatic approach. Heart 2003; 89: 605-9.
59. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, et al. Survival of patients with a new diagnosis of heart failure: A population based study. Heart 2000; 83: 505-10.
60. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38: 1934-41.
61. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J 2001; 22: 2164-70.
62. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, et al. Myocardial phosphocreatine- to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96: 2190-6.
63. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990; 11: 207-12.
64. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25: 1814-21.
65. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48(5): 999-1008.
66. Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008; 118(12): 1250-8.
67. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, Gonzalez-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002; 4(3): 331-6.
68. Fragasso G. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure Int J Clin Pract 2007, 61, 4, 603-10
69. Monti LD, Setola E, Fragasso G, Camisasca RP, Lucotti P, Galluccio E,et al. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab 2006; 290: E54-9.
70. Adams KF, Mathur VS, Gheorghiade M, Hill C: B-type natriuretic peptide: From bench to bedside. Am Heart J 2003; 145: S34-46
71. Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-22
72. Maisel A: Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. Clin Cornerstone 2005; 7: S7-17
73. Tsutamoto T, Wada A, Maeda K Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16
74. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure. A substudy of the carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Circulation 2004; 110: 1780-6
75. Bettencourt P, Azevedo A, Pimenta Fowler MB, Krum H, Mohacsi P J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168-74
76. Richards AM, Doughty R, Nicholls MG Macmahon S, Ikram H, Sharpe N, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999; 99: 786-92
77. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7
78. Sato Y, Taniguchi R, Makiyama T, Nagai K, Okada H, Yamada T, et al. Serum cardiac troponin T and plasma brain natriuretic peptide in patients with cardiac decompensation. Heart 2002: 88: 647-8
79. Perna ER, Macin SM, Parras JI, Pantich R, Farías EF, Badaracco JR, et al. Cardiac troponin T levels are associated with poor short-and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J 2002; 143: 814-20.
80. Di Napoli P, Di Giovanni P, Gaeta MA, D'Apolito G, Barsotti A. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J 2007; 154: 602-5.
81. El-Khady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: A 24-month study. Am J Cardiovasc Drugs 2005; 5(4): 271-8.
82. Kelle S, Weiss RG, Stuber M. Coronary magnetic resonance imaging. Curr Pharm Des 2008; 14(18): 1778-86.
83. Neglia D, Rimoldi O, Kaufmann PA, Camici PG. Radionuclide PET and PET/CT in coronary artery disease. Curr Pharm Des 2008; 14(18): 1798-814.
84. Vignati G, Annoni G. Characterization of supraventricular tachycardia in infants: Clinical and instrumental diagnosis. Curr Pharm Des 2008; 14(8): 729-35.